Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%

Part of paid clinical trials in Norfolk, Virginia.

Sponsor
Virginia Clinical Research, Inc.
Study ID
NCT06645821
Phase
EARLY_PHASE1
Status
Recruiting

Conditions

  • Hidradenitis Suppurativa (HS)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • EVO101 — DRUG
    EVO101 topical cream 0.1%

Study Details

The goal of this clinical trial is to learn if drug EVO101 works to treat mild to moderate hidradenitis suppurativa in adults. The main questions it aims to answer are: Does drug EVO101 lower the total number of lesion a participant has from the first visit to the last visit. What medical problems do participants have when applying drug EVO101 Does a participant perceive a change in their hidradenitis suppurativa symptoms based on patient reported outcome questionnaires. Participants will: Apply EVO101 topical cream 0.1% topically Visit the clinic four times unless the first and second appointment have to be done separately then there will be five clinic visits and one phone call over a twelve week period. Keep a dosing diary

Key Dates

Start date
Dec 3, 2024
Status verified
Dec 2024
Primary completion
Mar 31, 2025
Completion
May 31, 2025

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Open label EVO101 topical cream 0.1%
    All eligible subjects will receive open label EVO101 topical cream 0.1%

Primary Outcome Measure

The efficacy of EVO101 on hidradenitis suppurativa will be evaluated using two parameters: decrease in lesion count and change in patient reported outcomes (PRO) [ Time Frame: 12 Weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Virginia Clinical Research, Inc.NorfolkVirginia23502
Danielle Benedict
7576250151
Erin Rivera
757-625-0151
David M Pariser, MD

Find similar trials in Norfolk, VA

Related Studies